Pharmacologic targeting of this PDPN–β-catenin–PD-L1 pathway with the inhibitory peptide CY12-RP2 disrupts PDPN-driven immunosuppression within the tumor microenvironment, positioning this approach as a promising strategy for melanoma therapy. This evidence concerns the gene CD274 and neoplasm.